首页> 美国卫生研究院文献>Oncotarget >Clues toward precision medicine in oral squamous cell carcinoma: utility of next-generation sequencing for the prognostic stratification of high-risk patients harboring neck lymph node extracapsular extension
【2h】

Clues toward precision medicine in oral squamous cell carcinoma: utility of next-generation sequencing for the prognostic stratification of high-risk patients harboring neck lymph node extracapsular extension

机译:在口腔鳞状细胞癌中寻求精准医学的线索:下一代测序在具有颈部淋巴结包膜外扩展的高危患者的预后分层中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patients with resected oral squamous cell carcinoma (OSCC) harboring extracapsular extension (ECE) of the involved lymph node, show poor and heterogeneous outcomes. We aim to improve their prognostic stratification by combining genetic information from next-generation sequencing (NGS) using traditional clinicopathological prognosticators. The hotspot mutation regions of 45 cancer-related genes were investigated using NGS with an ultra-deep (>1000×) sequencing approach in formalin-fixed paraffin-embedded samples obtained from 201 patients with resected OSCC harboring ECE. Adjuvant chemoradiotherapy (CRT) and the number of nodes with ECE were the most important traditional prognosticators for disease-specific survival (DSS). The 5-year DSS for patients with CRT versus without, was 55% versus 21% (P < 0.001), and that for 1-3 versus ≥ 4 ECEs was 60% versus 25% (P = 0.001), respectively. Multivariate analysis in patients who received adjuvant CRT for 1-3 ECEs (i.e., those with a favorable expected prognosis) identified the following adverse prognostic factors: 1) margin of < 5 mm for locoregional failure (66% versus 30%, P = 0.007) and DSS (42% versus 63%, P = 0.039); 2) HRAS mutation for distant failure (55% versus 25%, P = 0.007) and DSS (36% versus 63%, P = 0.024); and 3) TP53 DNA-binding domain missense mutations for DSS (52% versus 71%, P = 0.025) and overall survival (39% versus 61%, P = 0.007).We conclude that genetic information from NGS may improve the prognostic stratification offered by traditional prognosticators in resected OSCC patients with ECE. Our findings will contribute to implementation of precision medicine in OSCC patients.
机译:切除的口腔鳞状细胞癌(OSCC)的患者所累及的淋巴结有囊外延伸(ECE),其结果差且异质。我们的目标是通过使用传统的临床病理学预后专家,结合来自下一代测序(NGS)的遗传信息来改善他们的预后分层。使用NGS和超深(> 1000×)测序方法在从201例切除了OSCC的带有ECE的OSCC患者中获得的福尔马林固定石蜡包埋的样本中,研究了45个与癌症相关的基因的热点突变区域。辅助放化疗(CRT)和伴有ECE的淋巴结数目是疾病特异性生存(DSS)最重要的传统预后指标。 CRT患者与非CRT患者的5年DSS分别为55%对21%(P <0.001),而1-3对≥4个ECE患者的5年DSS分别为60%对25%(P = 0.001)。对接受1-3个ECE的辅助CRT的患者(即预期预后良好的患者)进行多变量分析,确定了以下不良预后因素:1)局部区域衰竭的边距<5 mm(66%对30%,P = 0.007) )和DSS(42%对63%,P = 0.039); 2)HRAS突变用于远距离失败(55%对25%,P = 0.007)和DSS(36%对63%,P = 0.024);和3)DSS的TP53 DNA结合域错义突变(52%对71%,P = 0.025)和总生存(39% 61%, P = 0.007) )。我们得出的结论是,来自NGS的遗传信息可能会改善传统的预后评估者对已切除的OSCC ECE患者的预后分层。我们的发现将有助于在OSCC患者中实施精准医学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号